Cargando…
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Programmed cell death 1 (PD-1) signal receptor blockade has revolutionized the field of cancer therapy. Despite their considerable potential for treating certain cancers, drugs targeting PD-1 still present two main drawbacks: the substantial number of unresponsive patients and/or patients showing re...
Autores principales: | Chamoto, Kenji, Hatae, Ryusuke, Honjo, Tasuku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192862/ https://www.ncbi.nlm.nih.gov/pubmed/31900651 http://dx.doi.org/10.1007/s10147-019-01588-7 |
Ejemplares similares
-
Immune metabolism in PD-1 blockade-based cancer immunotherapy
por: Kumar, Alok, et al.
Publicado: (2020) -
Cancer immunotherapies targeting the PD-1 signaling pathway
por: Iwai, Yoshiko, et al.
Publicado: (2017) -
Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
por: Kumar, Alok, et al.
Publicado: (2020) -
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016) -
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)